Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Remegen Co. Ltd. currently has 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 5 distinct examiners and various art units. This distribution suggests a diverse set of applications moving through the patent office simultaneously. Such a spread across different units may lead to varied prosecution experiences and timelines for the company. The breadth of the portfolio indicates a multi-faceted research and development focus.
Connor Kennedy English is identified as the busiest examiner for the portfolio, with 1 pending office action. Although designated as the busiest, this examiner handles a portion of the 5 total pending actions, indicating that the workload is dispersed among the various examiners involved in the company's prosecution. For practitioners, this means that no individual examiner has an outsized influence on the portfolio, and success depends on navigating the different examiner relationships. Each of the pending office actions represents a unique path toward patent allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ENGLISH, CONNOR KENNEDY | 1 | 59.3% | +50.3% |
| BUCCINI, MICHELLE CALLAHAN | 1 | — | — |
| HA, JULIE | 1 | 75.7% | +44.1% |
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
| SKELDING, ZACHARY S | 1 | 59.8% | +41.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18725704 | METHOD FOR PREPARING AND PURIFYING MONOMETHYL AURISTATIN E INTERMEDIATE | ENGLISH, CONNOR KENNEDY | — |
| 17594768 | BISPECIFIC FUSION PROTEIN AND APPLICATION THEREOF | SKELDING, ZACHARY S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18725704 | METHOD FOR PREPARING AND PURIFYING MONOMETHYL AURISTATIN E INTERMEDIATE | ENGLISH, CONNOR KENNEDY | — |
| 18374902 | PREPARATION AND PURIFICATION PROCESS OF MONOMETHYL AURISTAIN E COMPOUND | HA, JULIE | — |
| 18450966 | USE OF ANTIBODY-DRUG CONJUGATE TARGETING HER2 IN TREATMENT OF SPECIFIC BREAST CANCER | PUTTLITZ, KARL J | — |
| 17594768 | BISPECIFIC FUSION PROTEIN AND APPLICATION THEREOF | SKELDING, ZACHARY S | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1675 | 1 |
| 1654 | 1 |
| 1646 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18725704 | METHOD FOR PREPARING AND PURIFYING MONOMETHYL AURISTATIN E INTERMEDIATE | ENGLISH, CONNOR KENNEDY | 1625 | §103§112 | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18511869 | USE OF HER2-TARGETING ANTIBODY-DRUG CONJUGATE IN TREATMENT OF HER2-LOW EXPRESSING BREAST CANCER | BUCCINI, MICHELLE CALLAHAN | 1675 | §103§112DP | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18374902 | PREPARATION AND PURIFICATION PROCESS OF MONOMETHYL AURISTAIN E COMPOUND | HA, JULIE | 1654 | §112 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18450966 | USE OF ANTIBODY-DRUG CONJUGATE TARGETING HER2 IN TREATMENT OF SPECIFIC BREAST CANCER | PUTTLITZ, KARL J | 1646 | §103DP | Final Rejection | — | Pending | Aug 16, 2023 |
| 17594768 | BISPECIFIC FUSION PROTEIN AND APPLICATION THEREOF | SKELDING, ZACHARY S | 1644 | §102§103§112 | Final Rejection | — | Pending | Oct 28, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRemegen Co. Ltd. has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Connor Kennedy English has the most, with 1 of Remegen Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
